{"id":"NCT01451164","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia","officialTitle":"A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-10","primaryCompletion":"2015-06","completion":null,"firstPosted":"2011-10-13","resultsPosted":"2019-10-03","lastUpdate":"2019-10-03"},"enrollment":459,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"OPC-34712","otherNames":[]},{"type":"DRUG","name":"OPC-34712","otherNames":[]},{"type":"DRUG","name":"OPC-34712","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"High dose","type":"EXPERIMENTAL"},{"label":"Mid dose","type":"EXPERIMENTAL"},{"label":"Low dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.","primaryOutcome":{"measure":"Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"Baseline, Weeks 1, 2, 3, 4, 5, and 6","effectByArm":[{"arm":"Brexpiprazole 1mg","deltaMin":-2.68,"sd":1.04},{"arm":"Brexpiprazole 2mg","deltaMin":-4.59,"sd":1.03},{"arm":"Brexpiprazole 4mg","deltaMin":-3.42,"sd":1.05},{"arm":"Placebo","deltaMin":-3.09,"sd":1.03}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":115},"commonTop":["Schizophrenia","Nasopharyngitis","Constipation","Headache","Vomiting"]}}